49 research outputs found
ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π°ΡΠΏΠ΅ΠΊΡΡ ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΠΏΠ΅ΡΠΈΡΠΎΠ½ΠΈΡΠ°, ΡΠ°Π·Π²ΠΈΠ²ΡΠ΅Π³ΠΎΡΡ ΠΏΠΎΡΠ»Π΅ ΡΠΈΡΡΡΠΊΡΠΎΠΌΠΈΠΈ
Background. Surgical morbidities of radical cystectomy, which are, as a rule, complicated intraabdominal infections, appear to be the main causes of repeated surgeries and fatal outcomes. The elimination of the infection Indus and an-timicrobic therapy are the currently accepted standard of treatment for postoperative peritonitis in cancer urology, as well as in general surgery hospital.Objective: defining the most reasonable option of surgical aid for peritonitis developing after cystectomy.Materials and methods. In the time period from 2000 through 2014, 58 cancer patients with postoperative peritonitis developing after cystectomy received indoor treatment at N.N. Alexandrov Republican Research and Practical Center for Oncology and Medical Radiology. Their mean age was 64.9 years, the range 44-90 years, 53 (91.4 %) of them being male. Primary urinary bladder cancer was present in 51 (87.9 %) patients. Peritoneal infection was microbiologically verified in 57 (98.3 %) patients. Each case of fatal outcome was associated with ineffective treatment of peritonitis. Depending on the intraoperative findings (presence or absence of a hollow organ defect) and the surgical approach undertaken (obstructive resection or operation maintaining the continuity of the intestinal and/or urinary tract), the patients were stratified into three groups: group 1 (n = 28), group 2 (n = 20) and group 3 (n = 10). There were no significant differences in the basic parameters specifying peritoneal infection severity between the patients of groups 1 and 2 vs group 3 (p >0.05).Results. Overall mortality amounted to 25.9 %, 15 patients died. Among the 28 (48.3 %) patients (group 1) who underwent obstructive elimination of the peritonitis focus by means of urointestinal reservoir ablation, resection of small or large intestine with ileo- or colostomy, 6 patients died, mortality 21.4 %. In the 10 (17.2 %) patients (group 3) who succeeded in preserving the urinary conduit or continuity of the bowels by anastomosis defect closure, resection of enteroentero-anastomosis or urointestinal reservoir with repeated anastomosing or defect closure, mortality was higher (60 %) (p = 0.045); 6 patients died.Conclusion. The most effective option of surgical treatment of postoperative peritonitis developing after cystectomy is obstructive reoperation on the bowels and urinary tracts: compared with the intervention consisting in preserving the urinary conduit and/or continuity of the intestinal tract, this type of surgery caused a 2.8-fold lower mortality.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. Π₯ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΡ ΡΠ°Π΄ΠΈΠΊΠ°Π»ΡΠ½ΠΎΠΉ ΡΠΈΡΡΡΠΊΡΠΎΠΌΠΈΠΈ, ΡΠ°ΠΊΠΈΠ΅ ΠΊΠ°ΠΊ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½Π½ΡΠ΅ ΠΈΠ½ΡΡΠ°Π°Π±Π΄ΠΎΠΌΠΈΠ½Π°Π»ΡΠ½ΡΠ΅ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΠΈ ΠΊΠΈΡΠ΅ΡΠ½Π°Ρ Π½Π΅ΠΏΡΠΎΡ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΡ, - ΠΎΡΠ½ΠΎΠ²Π½ΡΠ΅ ΠΏΡΠΈΡΠΈΠ½Ρ ΠΏΠΎΠ²ΡΠΎΡΠ½ΡΡ
ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΉ ΠΈ Π»Π΅ΡΠ°Π»ΡΠ½ΡΡ
ΠΈΡΡ
ΠΎΠ΄ΠΎΠ². ΠΠ±ΡΠ΅ΠΏΡΠΈΠ½ΡΡΡΠΌ ΡΡΠ°Π½Π΄Π°ΡΡΠΎΠΌ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΠΏΠ΅ΡΠΈΡΠΎΠ½ΠΈΡΠ° Π² ΠΎΠ½ΠΊΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΠΈ, ΠΊΠ°ΠΊ ΠΈ Π² ΠΎΠ±ΡΠ΅Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΌ ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ΅, ΡΠ²Π»ΡΡΡΡΡ ΡΡΡΡΠ°Π½Π΅Π½ΠΈΠ΅ ΠΎΡΠ°Π³Π° ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΠΈ Π°Π½ΡΠΈΠΌΠΈΠΊΡΠΎΠ±Π½Π°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ - ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΠΏΡΠΈΠ΅ΠΌΠ»Π΅ΠΌΡΠΉ Π²Π°ΡΠΈΠ°Π½Ρ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΠΎΡΠΎΠ±ΠΈΡ ΠΏΡΠΈ ΠΏΠ΅ΡΠΈΡΠΎΠ½ΠΈΡΠ΅, ΡΠ°Π·Π²ΠΈΠ²ΡΠ΅ΠΌΡΡ ΠΏΠΎΡΠ»Π΅ ΡΠΈΡΡΡΠΊΡΠΎΠΌΠΈΠΈ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΏΠ΅ΡΠΈΠΎΠ΄ Ρ 2000 ΠΏΠΎ 2014 Π³. Π² Π Π΅ΡΠΏΡΠ±Π»ΠΈΠΊΠ°Π½ΡΠΊΠΎΠΌ Π½Π°ΡΡΠ½ΠΎ-ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΎΠΌ ΡΠ΅Π½ΡΡΠ΅ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΉ ΡΠ°Π΄ΠΈΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈΠΌ. Π.Π. ΠΠ»Π΅ΠΊΡΠ°Π½Π΄ΡΠΎΠ²Π° Π½Π° ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ½ΠΎΠΌ Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π½Π°Ρ
ΠΎΠ΄ΠΈΠ»ΠΈΡΡ 58 ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (ΠΈΠ· Π½ΠΈΡ
53 (91,4 %) ΠΌΡΠΆΡΠΈΠ½Ρ) Ρ ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΡΠΌ ΠΏΠ΅ΡΠΈΡΠΎΠ½ΠΈΡΠΎΠΌ, ΠΊΠΎΡΠΎΡΡΠΉ ΡΠ°Π·Π²ΠΈΠ»ΡΡ ΠΏΠΎΡΠ»Π΅ ΡΠΈΡΡΡΠΊΡΠΎΠΌΠΈΠΈ. Π‘ΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ - 64,9 (44-90) Π³ΠΎΠ΄Π°. ΠΠ΅ΡΠ²ΠΈΡΠ½ΡΠΉ ΡΠ°ΠΊ ΠΌΠΎΡΠ΅Π²ΠΎΠ³ΠΎ ΠΏΡΠ·ΡΡΡ Π·Π°ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π½ Ρ 51 (87,9 %) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°. ΠΠΈΠΊΡΠΎΠ±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π΅Π½ΠΈΠ΅ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Π±ΡΡΡΠΈΠ½Ρ ΠΈΠΌΠ΅Π»ΠΎΡΡ Ρ 57 (98,3 %) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². ΠΠ°ΠΆΠ΄ΡΠΉ ΡΠ»ΡΡΠ°ΠΉ Π»Π΅ΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈΡΡ
ΠΎΠ΄Π° Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½ Ρ Π½Π΅ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΡ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΠ΅ΡΠΈΡΠΎΠ½ΠΈΡΠ°. Π Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ ΠΈΠ½ΡΡΠ°ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΡΡ
Π΄Π°Π½Π½ΡΡ
(Π½Π°Π»ΠΈΡΠΈΠ΅ ΠΈΠ»ΠΈ ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ Π΄Π΅ΡΠ΅ΠΊΡΠ° ΠΏΠΎΠ»ΠΎΠ³ΠΎ ΠΎΡΠ³Π°Π½Π°) ΠΈ ΠΏΡΠ΅Π΄ΠΏΡΠΈΠ½ΡΡΠΎΠΉ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ°ΠΊΡΠΈΠΊΠΈ (ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½Π°Ρ ΡΠ΅Π·Π΅ΠΊΡΠΈΡ ΠΈΠ»ΠΈ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΡ Ρ ΡΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΠ΅ΠΌ Π½Π΅ΠΏΡΠ΅ΡΡΠ²Π½ΠΎΡΡΠΈ ΠΊΠΈΡΠ΅ΡΠ½ΠΎΠ³ΠΎ ΠΈ/ΠΈΠ»ΠΈ ΠΌΠΎΡΠ΅Π²ΠΎΠ³ΠΎ ΡΡΠ°ΠΊΡΠ°) ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ Π±ΡΠ»ΠΈ ΡΡΡΠ°ΡΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Ρ Π½Π° 3 Π³ΡΡΠΏΠΏΡ: Π² 1-Ρ Π³ΡΡΠΏΠΏΡ Π²ΠΎΡΠ»ΠΈ 28 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², Π²ΠΎ 2-Ρ - 20, Π² 3-Ρ - 10. Π‘ΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
ΡΠ°Π·Π»ΠΈΡΠΈΠΉ ΠΏΠΎ ΠΎΡΠ½ΠΎΠ²Π½ΡΠΌ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠ°ΠΌ, Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΡΡΠΈΠΌ ΡΡΠΆΠ΅ΡΡΡ ΠΏΠ΅ΡΠΈΡΠΎΠ½Π΅Π°Π»ΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ, ΡΡΠ΅Π΄ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² 1-ΠΉ ΠΈ 2-ΠΉ Π³ΡΡΠΏΠΏ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ 3-ΠΉ Π½Π΅ Π±ΡΠ»ΠΎ (Ρ >0,05).Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠ±ΡΠ°Ρ Π»Π΅ΡΠ°Π»ΡΠ½ΠΎΡΡΡ ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 25,9 %; ΡΠΌΠ΅ΡΠ»ΠΈ 15 ΡΠ΅Π»ΠΎΠ²Π΅ΠΊ. Π‘ΡΠ΅Π΄ΠΈ 28 (48,3 %) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² 1-ΠΉ Π³ΡΡΠΏΠΏΡ, ΠΊΠΎΡΠΎΡΡΠΌ Π»ΠΈΠΊΠ²ΠΈΠ΄Π°ΡΠΈΡ ΠΈΡΡΠΎΡΠ½ΠΈΠΊΠ° ΠΏΠ΅ΡΠΈΡΠΎΠ½ΠΈΡΠ° ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ ΠΏΠΎ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠΌΡ ΡΠΈΠΏΡ ΠΏΡΡΠ΅ΠΌ ΡΠ΄Π°Π»Π΅Π½ΠΈΡ ΠΌΠΎΡΠ΅ΠΊΠΈΡΠ΅ΡΠ½ΠΎΠ³ΠΎ ΡΠ΅Π·Π΅ΡΠ²ΡΠ°ΡΠ°, ΡΠ΅Π·Π΅ΠΊΡΠΈΠ΅ΠΉ ΡΠΎΠ½ΠΊΠΎΠ³ΠΎ ΠΈΠ»ΠΈ ΡΠΎΠ»ΡΡΠΎΠ³ΠΎ ΠΊΠΈΡΠ΅ΡΠ½ΠΈΠΊΠ° Ρ ΠΈΠ»Π΅ΠΎ- ΠΈΠ»ΠΈ ΠΊΠΎΠ»ΠΎΡΡΠΎΠΌΠΈΠ΅ΠΉ, ΡΠΌΠ΅ΡΠ»ΠΈ 6 ΡΠ΅Π»ΠΎΠ²Π΅ΠΊ; Π»Π΅ΡΠ°Π»ΡΠ½ΠΎΡΡΡ - 21,4 %. ΠΠ· 10 (17,2 %) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² 3-ΠΉ Π³ΡΡΠΏΠΏΡ, ΠΊΠΎΡΠΎΡΡΠΌ ΡΠ΄Π°Π»ΠΎΡΡ ΡΠΎΡ
ΡΠ°Π½ΠΈΡΡ ΠΌΠΎΡΠ΅Π²ΠΎΠΉ ΠΊΠΎΠ½Π΄ΡΠΈΡ ΠΈΠ»ΠΈ Π½Π΅ΠΏΡΠ΅ΡΡΠ²Π½ΠΎΡΡΡ ΠΊΠΈΡΠ΅ΡΠ½ΠΈΠΊΠ° ΡΡΠΈΠ²Π°Π½ΠΈΠ΅ΠΌ Π΄Π΅ΡΠ΅ΠΊΡΠ° Π² Π°Π½Π°ΡΡΠΎΠΌΠΎΠ·Π΅, ΡΠ΅Π·Π΅ΠΊΡΠΈΠ΅ΠΉ ΠΌΠ΅ΠΆΠΊΠΈΡΠ΅ΡΠ½ΠΎΠ³ΠΎ ΡΠΎΡΡΡΡΡ ΠΈΠ»ΠΈ ΠΌΠΎΡΠ΅ΠΊΠΈΡΠ΅ΡΠ½ΠΎΠ³ΠΎ ΡΠ΅Π·Π΅ΡΠ²ΡΠ°ΡΠ° Ρ ΠΏΠΎΠ²ΡΠΎΡΠ½ΡΠΌ Π°Π½Π°ΡΡΠΎΠΌΠΎΠ·ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΈΠ»ΠΈ ΡΡΠΈΠ²Π°Π½ΠΈΠ΅ΠΌ Π΄Π΅ΡΠ΅ΠΊΡΠ°, Π»Π΅ΡΠ°Π»ΡΠ½ΠΎΡΡΡ Π±ΡΠ»Π° Π²ΡΡΠ΅ - 60 % (Ρ = 0,045); ΡΠΌΠ΅ΡΠ»ΠΈ 6 ΡΠ΅Π»ΠΎΠ²Π΅ΠΊ.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠ°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΈΠ²Π½ΡΠΌ Π²Π°ΡΠΈΠ°Π½ΡΠΎΠΌ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΠΏΠ΅ΡΠΈΡΠΎΠ½ΠΈΡΠ°, ΡΠ°Π·Π²ΠΈΠ²ΡΠ΅Π³ΠΎΡΡ ΠΏΠΎΡΠ»Π΅ ΡΠΈΡΡΡΠΊΡΠΎΠΌΠΈΠΈ, ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½Π°Ρ ΡΠ΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΡ Π½Π° ΠΊΠΈΡΠ΅ΡΠ½ΠΈΠΊΠ΅ ΠΈ ΠΌΠΎΡΠ΅Π²ΡΡ
ΠΏΡΡΡΡ
. ΠΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ Π²ΠΌΠ΅ΡΠ°ΡΠ΅Π»ΡΡΡΠ²ΠΎΠΌ, ΡΠΎΡΡΠΎΡΡΠΈΠΌ Π² ΡΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΠΈ ΠΌΠΎΡΠ΅Π²ΠΎΠ³ΠΎ ΠΊΠΎΠ½Π΄ΡΠΈΡΠ° ΠΈ/ΠΈΠ»ΠΈ Π½Π΅ΠΏΡΠ΅ΡΡΠ²Π½ΠΎΡΡΠΈ ΠΊΠΈΡΠ΅ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ°ΠΊΡΠ°, ΠΏΡΠΈ Π΄Π°Π½Π½ΠΎΠΌ ΡΠΈΠΏΠ΅ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΈ Π»Π΅ΡΠ°Π»ΡΠ½ΠΎΡΡΡ Π±ΡΠ»Π° Π² 2,8 ΡΠ°Π·Π° Π½ΠΈΠΆΠ΅
Recommended from our members
Orbit: A Code for Collective Beam Dynamics in High Intensity Rings.
We are developing a computer code, ORBIT, specifically for beam dynamics calculations in high-intensity rings. Our approach allows detailed simulation of realistic accelerator problems. ORBIT is a particle-in-cell tracking code that transports bunches of interacting particles through a series of nodes representing elements, effects, or diagnostics that occur in the accelerator lattice. At present, ORBIT contains detailed models for strip-foil injection, including painting and foil scattering; rf focusing and acceleration; transport through various magnetic elements; longitudinal and transverse impedances; longitudinal, transverse, and three-dimensional space charge forces; collimation and limiting apertures; and the calculation of many useful diagnostic quantities. ORBIT is an object-oriented code, written in C++ and utilizing a scripting interface for the convenience of the user. Ongoing improvements include the addition of a library of accelerator maps, BEAMLINE/MXYZPTLK, the introduction of a treatment of magnet errors and fringe fields; the conversion of the scripting interface to the standard scripting language, Python; and the parallelization of the computations using MPI. The ORBIT code is an open source, powerful, and convenient tool for studying beam dynamics in high-intensity rings
OPEN XAL Status Report 2015
MOPW1050International audienceOpen XAL is an accelerator physics software platformdeveloped in collaboration among several facilitiesaround the world. The Open XAL collaboration wasformed in 2010 to port, improve and extend the successfulXAL platform used at the Spallation Neutron Source foruse in the broader accelerator community and to establishit as the standard platform for accelerator physicssoftware. The site-independent core is complete, activeapplications have been ported, and now we are in theprocess of verification and transitioning to using OpenXAL in production. This paper will present the currentstatus and a roadmap for this project
Open XAL status Report 2015
Open XAL is an accelerator physics software platform developed in collaboration among several facilities around the world. The Open XAL collaboration was formed in 2010 to port, improve and extend the successful XAL platform used at the Spallation Neutron Source for use in the broader accelerator community and to establish it as the standard platform for accelerator physics software. The site-independent core is complete, active applications have been ported, and now we are in the process of verification and transitioning to using Open XAL in production. This paper will present the current status and a roadmap for this project
Π§ΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΊ Π³Π»ΡΠΊΠΎΠΊΠΎΡΡΠΈΠΊΠΎΡΡΠ΅ΡΠΎΠΈΠ΄Π°ΠΌ ΠΈ Π³Π΅ΡΠ΅ΡΠΎΠ³Π΅Π½Π½ΠΎΡΡΡ ΠΎΡΠ²Π΅ΡΠ° ΠΊΠ»Π΅ΡΠΎΠΊ in vitro Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΡΡ Π»Π΅Π³ΠΊΠΈΡ
Inhaled corticosteroids are widely used for the treatment of chronic obstructive pulmonary disease (COPD), but their efficacy significantly varies between patients. The aim of the study was to establish approaches to reveal steroid-sensitive and steroid-resistant patients with COPD using the blood and lung cells. Methods. Forty five patients with COPD undergoing bronchoscopy were recruited for the study of cytokine secretion by alveolar macrophages under the influence of glucocorticoids. Alveolar macrophages isolated from bronchoalveolar lavage fluid were cultured with lipopolysaccharide (LPS) and different concentrations of dexamethasone (0.01 β 1000 nM) for 24 h. Then, supernatants were removed and analyzed for concentrations of interleukin 6 (IL-6), IL-8 and tumor necrosis factor Ξ± (TNF-Ξ±). Binding of the glucocorticoid with its receptors was investigated in 24 patients with COPD, 20 healthy smokers and 20 healthy non-smokers. Blood cells were cultured with fluorescein isothiocyanate (FITC)-labelled dexamethasone and monoclonal antibodies against surface antigens of lymphocyte and monocyte populations. Fluorescence intensity of FITC-labelled dexamethasone was analyzed in blood cells using flow cytometry. Results. Dexamethasone significantly inhibited IL-6, IL-8, and TNF-Ξ± production in alveolar macrophages in a dose dependent manner. The maximal inhibition of cytokine production was observed at dexamethasone concentration of 100 nM, and the maximal cell response variability was found at 10 nM. IL-8 was less sensitive to the corticosteroid compared to IL-6 and TNF-Ξ±. Dexamethasone at any concentration failed to reach >50% inhibition of LPS-induced production of IL-8, IL-6 and TNF-Ξ± in alveolar macrophages of 40.0%; 11.1% and 8.9% of COPD patients, respectively. The fluorescence intensity of FITC-labelled dexamethasone in blood lymphocytes and monocytes was lower in smokers with COPD compared to healthy smokers and healthy non-smokers. The binding of dexamethasone with its receptors in the blood cells was higher in healthy non-smokers compared to healthy smokers. Conclusion. In vitro response of alveolar macrophages to glucocorticoids in COPD patients is characterized by significant inter-individual variability. The weak corticosteroid-related inhibition of IL-8 production can contribute to neutrophilic inflammation in COPD. The capacity of glucocorticoid receptors to bind with their ligands in blood lymphocytes and monocytes is decreased in COPD patients.ΠΠ½Π³Π°Π»ΡΡΠΈΠΎΠ½Π½ΡΠ΅ Π³Π»ΡΠΊΠΎΠΊΠΎΡΡΠΈΠΊΠΎΡΡΠ΅ΡΠΎΠΈΠ΄Ρ (ΠΈΠΠΠ‘) ΡΠΈΡΠΎΠΊΠΎ ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΡΡΡΡ Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΡΡ Π»Π΅Π³ΠΊΠΈΡ
(Π₯ΠΠΠ), ΠΎΠ΄Π½Π°ΠΊΠΎ ΠΈΡ
ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΡΠ°Π·Π»ΠΈΡΠ°Π΅ΡΡΡ. Π¦Π΅Π»ΡΡ Π½Π°ΡΡΠΎΡΡΠ΅Π³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ²ΠΈΠ»ΠΎΡΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄ΠΎΠ² ΠΊ Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π₯ΠΠΠ, ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΠΈ Π½Π΅ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΠΊ ΠΠΠ‘, ΠΏΡΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠΈ ΠΊΠ»Π΅ΡΠΎΠΊ Π»Π΅Π³ΠΊΠΈΡ
ΠΈ ΠΊΡΠΎΠ²ΠΈ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΡΠΈΡΠΎΠΊΠΈΠ½-ΡΠ΅ΠΊΡΠ΅ΡΠΈΡΡΡΡΠ΅ΠΉ ΡΡΠ½ΠΊΡΠΈΠΈ Π°Π»ΡΠ²Π΅ΠΎΠ»ΡΡΠ½ΡΡ
ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΎΠ² (ΠΠ) ΠΏΠΎΠ΄ Π²Π»ΠΈΡΠ½ΠΈΠ΅ΠΌ ΠΠΠ‘ ΠΏΡΠΈΠ½ΡΠ»ΠΈ ΡΡΠ°ΡΡΠΈΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ (n = 45), ΠΊΠΎΡΠΎΡΡΠΌ Π²ΡΠΏΠΎΠ»Π½ΡΠ»Π°ΡΡ Π±ΡΠΎΠ½Ρ
ΠΎΡΠΊΠΎΠΏΠΈΡ. ΠΠ, Π²ΡΠ΄Π΅Π»Π΅Π½Π½ΡΠ΅ ΠΈΠ· Π±ΡΠΎΠ½Ρ
ΠΎΠ°Π»ΡΠ²Π΅ΠΎΠ»ΡΡΠ½ΠΎΠΉ Π»Π°Π²Π°ΠΆΠ½ΠΎΠΉ ΠΆΠΈΠ΄ΠΊΠΎΡΡΠΈ, ΠΊΡΠ»ΡΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π»ΠΈΡΡ Ρ Π»ΠΈΠΏΠΎΠΏΠΎΠ»ΠΈΡΠ°Ρ
Π°ΡΠΈΠ΄ΠΎΠΌ ΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠΌΠΈ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡΠΌΠΈ Π΄Π΅ΠΊΡΠ°ΠΌΠ΅ΡΠ°Π·ΠΎΠ½Π° (0,01β1Β 000 Π½Π). ΠΠΎ ΠΈΡΡΠ΅ΡΠ΅Π½ΠΈΠΈ 1 ΡΡΡΠΎΠΊ ΡΠΎΠ±ΠΈΡΠ°Π»ΠΈΡΡ ΡΡΠΏΠ΅ΡΠ½Π°ΡΠ°Π½ΡΡ, Π² Π½ΠΈΡ
ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»Π°ΡΡ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ ΠΈΠ½ΡΠ΅ΡΠ»Π΅ΠΉΠΊΠΈΠ½Π° (IL)-6, IL-8 ΠΈ ΡΠ°ΠΊΡΠΎΡΠ° Π½Π΅ΠΊΡΠΎΠ·Π° ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ-Ξ± (TNF-Ξ±). ΠΠ»Ρ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΡ ΠΠΠ‘ ΠΈ ΠΈΡ
ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠΎΠ² ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ Ρ Π₯ΠΠΠ (n = 24), Π·Π΄ΠΎΡΠΎΠ²ΡΠ΅ ΠΊΡΡΠΈΠ»ΡΡΠΈΠΊΠΈ (n = 20) ΠΈ Π·Π΄ΠΎΡΠΎΠ²ΡΠ΅ Π½Π΅ΠΊΡΡΡΡΠΈΠ΅ (n = 20). ΠΠ»Π΅ΡΠΊΠΈ ΠΊΡΠΎΠ²ΠΈ ΠΊΡΠ»ΡΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π»ΠΈΡΡ Ρ Π΄Π΅ΠΊΡΠ°ΠΌΠ΅ΡΠ°Π·ΠΎΠ½ΠΎΠΌ, ΠΌΠ΅ΡΠ΅Π½Π½ΡΠΌ ΡΠ»ΡΠΎΡΠ΅ΡΡΠ΅ΠΈΠ½ΠΈΠ·ΠΎΡΠΈΠΎΡΠΈΠ°Π½Π°ΡΠΎΠΌ (FITC) ΠΈ ΠΌΠΎΠ½ΠΎΠΊΠ»ΠΎΠ½Π°Π»ΡΠ½ΡΠΌΠΈ Π°Π½ΡΠΈΡΠ΅Π»Π°ΠΌΠΈ ΠΊ ΠΏΠΎΠ²Π΅ΡΡ
Π½ΠΎΡΡΠ½ΡΠΌ Π°Π½ΡΠΈΠ³Π΅Π½Π°ΠΌ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΉ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² ΠΈ ΠΌΠΎΠ½ΠΎΡΠΈΡΠΎΠ². ΠΠ½Π°Π»ΠΈΠ· ΠΈΠ½ΡΠ΅Π½ΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠ»ΡΠΎΡΠ΅ΡΡΠ΅Π½ΡΠΈΠΈ FITC-ΠΌΠ΅ΡΠ΅Π½Π½ΠΎΠ³ΠΎ Π΄Π΅ΠΊΡΠ°ΠΌΠ΅ΡΠ°Π·ΠΎΠ½Π° Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ
ΠΊΡΠΎΠ²ΠΈ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΡΡ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΏΡΠΎΡΠΎΡΠ½ΠΎΠΉ ΡΠΈΡΠΎΠΌΠ΅ΡΡΠΈΠΈ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΡΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠΈ Π΄Π΅ΠΊΡΠ°ΠΌΠ΅ΡΠ°Π·ΠΎΠ½Π° Π΄ΠΎΠ·ΠΎΠ·Π°Π²ΠΈΡΠΈΠΌΠΎ ΡΠ½ΠΈΠΆΠ°Π»Π°ΡΡ ΡΠ΅ΠΊΡΠ΅ΡΠΈΡ IL-6, IL-8 ΠΈ TNF-Ξ± ΠΠ. ΠΠ°ΠΊΡΠΈΠΌΠ°Π»ΡΠ½ΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΠΈ ΡΠΈΡΠΎΠΊΠΈΠ½ΠΎΠ² ΠΠ Π½Π°Π±Π»ΡΠ΄Π°Π»ΠΎΡΡ ΠΏΡΠΈ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ Π΄Π΅ΠΊΡΠ°ΠΌΠ΅ΡΠ°Π·ΠΎΠ½Π° 100 Π½Π, Π° Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠ°Ρ ΡΡΠ΅ΠΏΠ΅Π½Ρ Π²Π°ΡΠΈΠ°Π±Π΅Π»ΡΠ½ΠΎΡΡΠΈ ΠΎΡΠ²Π΅ΡΠ° ΠΊΠ»Π΅ΡΠΎΠΊ β ΠΏΡΠΈ 10 Π½Π. IL-8 Π±ΡΠ» ΠΌΠ΅Π½Π΅Π΅ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»Π΅Π½ ΠΊ ΠΈΠΠΠ‘, ΡΠ΅ΠΌ IL-6 ΠΈ TNF-Ξ±. ΠΡΠΈ Π»ΡΠ±ΠΎΠΉ ΠΈΠ· ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΠ΅ΠΌΡΡ
ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΉ Π΄Π΅ΠΊΡΠ°ΠΌΠ΅ΡΠ°Π·ΠΎΠ½ Π½Π΅ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΠ²Π°Π» Π±ΠΎΠ»Π΅Π΅ ΡΠ΅ΠΌ Π½Π° 50 % ΠΈΠ½Π΄ΡΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΡ IL-8 Π² ΠΠ Ρ 40 % ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π₯ΠΠΠ, IL-6 β Ρ 11,1 %, TNF-Ξ± β Ρ 8,9 %. Π£ ΠΊΡΡΡΡΠΈΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π₯ΠΠΠ ΠΈΠ½ΡΠ΅Π½ΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠ»ΡΠΎΡΠ΅ΡΡΠ΅Π½ΡΠΈΠΈ FITC-ΠΌΠ΅ΡΠ΅Π½Π½ΠΎΠ³ΠΎ Π΄Π΅ΠΊΡΠ°ΠΌΠ΅ΡΠ°Π·ΠΎΠ½Π° Π² ΠΏΠΎΠΏΡΠ»ΡΡΠΈΡΡ
Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² ΠΈ ΠΌΠΎΠ½ΠΎΡΠΈΡΠ°Ρ
ΠΊΡΠΎΠ²ΠΈ ΠΎΠΊΠ°Π·Π°Π»Π°ΡΡ Π½ΠΈΠΆΠ΅, ΡΠ΅ΠΌ Ρ ΠΊΡΡΡΡΠΈΡ
ΠΈ Π½Π΅ΠΊΡΡΡΡΠΈΡ
Π·Π΄ΠΎΡΠΎΠ²ΡΡ
. Π‘Π²ΡΠ·ΡΠ²Π°Π½ΠΈΠ΅ Π΄Π΅ΠΊΡΠ°ΠΌΠ΅ΡΠ°Π·ΠΎΠ½Π° ΡΠΎ ΡΠ²ΠΎΠΈΠΌΠΈ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠ°ΠΌΠΈ Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ
ΠΊΡΠΎΠ²ΠΈ Π±ΡΠ»ΠΎ Π²ΡΡΠ΅ Ρ Π½Π΅ΠΊΡΡΡΡΠΈΡ
Π·Π΄ΠΎΡΠΎΠ²ΡΡ
, ΡΠ΅ΠΌ Ρ Π·Π΄ΠΎΡΠΎΠ²ΡΡ
ΠΊΡΡΠΈΠ»ΡΡΠΈΠΊΠΎΠ². ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π₯ΠΠΠ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΠ΅ΡΡΡ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΠΌΠ΅ΠΆΠΈΠ½Π΄ΠΈΠ²ΠΈΠ΄ΡΠ°Π»ΡΠ½ΠΎΠΉ Π²Π°ΡΠΈΠ°Π±Π΅Π»ΡΠ½ΠΎΡΡΡΡ in vitro ΠΎΡΠ²Π΅ΡΠ° ΠΠ Π½Π° ΠΠΠ‘. ΠΠ³ΡΠ°Π½ΠΈΡΠ΅Π½Π½ΠΎΠ΅ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠΈΠ½ΡΠ΅Π·Π° IL-8 ΠΠΠ‘ ΠΌΠΎΠΆΠ΅Ρ ΡΠΏΠΎΡΠΎΠ±ΡΡΠ²ΠΎΠ²Π°ΡΡ ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠ°Π½ΠΈΡ Π½Π΅ΠΉΡΡΠΎΡΠΈΠ»ΡΠ½ΠΎΠ³ΠΎ ΡΠΈΠΏΠ° Π²ΠΎΡΠΏΠ°Π»Π΅Π½ΠΈΡ ΠΏΡΠΈ Π₯ΠΠΠ. ΠΠ»Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π₯ΠΠΠ ΡΠ²ΠΎΠΉΡΡΠ²Π΅Π½Π½ΠΎ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΠΈ ΠΠΠ‘-ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠΎΠ² ΡΠ²ΡΠ·ΡΠ²Π°ΡΡΡΡ ΡΠΎ ΡΠ²ΠΎΠΈΠΌΠΈ Π»ΠΈΠ³Π°Π½Π΄Π°ΠΌΠΈ Π² Π»ΠΈΠΌΡΠΎΡΠΈΡΠ°Ρ
ΠΈ ΠΌΠΎΠ½ΠΎΡΠΈΡΠ°Ρ
ΠΊΡΠΎΠ²ΠΈ
Recommended from our members
Accelerator Physics Code Web Repository
In the framework of the CARE HHH European Network, we have developed a web-based dynamic acceleratorphysics code repository. We describe the design, structure and contents of this repository, illustrate its usage, and discuss our future plans, with emphasis on code benchmarking
ΠΠΠΠΠ’Π ΠΠΠ‘ΠΠΠΠΠ’ΠΠ¦ΠΠ― ΠΠΠ-ΠΠΠ‘ΠΠΠΠΠ‘Π’ΠΠΠ«Π₯ ΠΠΠ§ΠΠ Π£ ΠΠΠ’ΠΠ
At present the problem of donor organs for transplantation shortage remains unsolved. Cautious and mixed attitude towards the transplantation of incompatible kidneys remains, while it could considerably reduce the donor organ waiting time for a recipient. Experience of 19 allotransplantations of ABO-incompatible kidneys in children is analyzed in the article. A group of 14 patients who received ABOcompatible kidneys was chosen for the comparative analysis. Such parameters as the assessment of function of allotransplanted kidneys, morphology character comparison of biopsy materials of allo-kidneys in both groups, actuarial survival rate of the recipients with functioning allografts are used to assess the results. Comparison of the aforementioned parameters showed practically the same results, and that enables us to assert that transplantations of kidneys of ABO-incompatible donors have the right to exist.Π Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ ΠΎΡΡΠ°Π΅ΡΡΡ Π½Π΅ΡΠ΅ΡΠ΅Π½Π½ΠΎΠΉ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ° Π½Π΅Ρ
Π²Π°ΡΠΊΠΈ Π΄ΠΎΠ½ΠΎΡΡΠΊΠΈΡ
ΠΎΡΠ³Π°Π½ΠΎΠ² Π΄Π»Ρ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ. Π‘ΠΎΡ
ΡΠ°Π½ΡΠ΅ΡΡΡ Π½Π°ΡΡΠΎΡΠΎΠΆΠ΅Π½Π½ΠΎΠ΅, Π½Π΅ΠΎΠ΄Π½ΠΎΠ·Π½Π°ΡΠ½ΠΎΠ΅ ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅ ΠΊ ΠΏΠ΅ΡΠ΅ΡΠ°Π΄ΠΊΠ΅ Π½Π΅ΡΠΎΠ²ΠΌΠ΅ΡΡΠΈΠΌΡΡ
ΠΏΠΎΡΠ΅ΠΊ, ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΊΠΎΡΠΎΡΡΡ
ΠΌΠΎΠ³Π»ΠΎ Π±Ρ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΡΠΎΠΊΡΠ°ΡΠΈΡΡ Π²ΡΠ΅ΠΌΡ ΠΎΠΆΠΈΠ΄Π°Π½ΠΈΡ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠΌ Π΄ΠΎΠ½ΠΎΡΡΠΊΠΎΠ³ΠΎ ΠΎΡΠ³Π°Π½Π°. Π ΡΡΠ°ΡΡΠ΅ ΠΏΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½ ΠΎΠΏΡΡ 19 Π°Π»Π»ΠΎΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΉ ΠΠ0-Π½Π΅ΡΠΎΠ²ΠΌΠ΅ΡΡΠΈΠΌΡΡ
ΠΏΠΎΡΠ΅ΠΊ Ρ Π΄Π΅ΡΠ΅ΠΉ. ΠΠ»Ρ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° Π²ΡΠ±ΡΠ°Π½Π° Π³ΡΡΠΏΠΏΠ° ΠΈΠ· 14 Π±ΠΎΠ»ΡΠ½ΡΡ
, ΠΊΠΎΡΠΎΡΡΠΌ Π²ΡΠΏΠΎΠ»Π½Π΅Π½Ρ ΠΏΠ΅ΡΠ΅ΡΠ°Π΄ΠΊΠΈ ΠΠ0-ΡΠΎΠ²ΠΌΠ΅ΡΡΠΈΠΌΡΡ
ΠΏΠΎΡΠ΅ΠΊ. ΠΠ»Ρ ΠΎΡΠ΅Π½ΠΊΠΈ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½Ρ ΡΠ°ΠΊΠΈΠ΅ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΡ, ΠΊΠ°ΠΊ ΠΎΡΠ΅Π½ΠΊΠ° ΡΡΠ½ΠΊΡΠΈΠΈ Π°Π»Π»ΠΎΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΏΠΎΡΠ΅ΠΊ, ΡΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠ° ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΠΈ Π±ΠΈΠΎΠΏΡΠ°ΡΠΎΠ² Π°Π»Π»ΠΎΠΏΠΎΡΠ΅ΠΊ Π² ΠΎΠ±Π΅ΠΈΡ
Π³ΡΡΠΏΠΏΠ°Ρ
, ΠΎΡΠ΅Π½ΠΊΠ° Π°ΠΊΡΡΠ°ΡΠ½ΠΎΠΉ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΡΠ½ΠΊΡΠΈΠΎΠ½ΠΈΡΡΡΡΠΈΠΌΠΈ Π°Π»Π»ΠΎΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠ°ΠΌΠΈ. Π‘ΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ Π²ΡΡΠ΅ΠΏΠ΅ΡΠ΅ΡΠΈΡΠ»Π΅Π½Π½ΡΡ
ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΎΠ² ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΎ ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈ ΠΎΠ΄ΠΈΠ½Π°ΠΊΠΎΠ²ΡΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ, ΡΡΠΎ Π΄Π°Π΅Ρ Π½Π°ΠΌ ΠΏΡΠ°Π²ΠΎ ΡΡΠ²Π΅ΡΠΆΠ΄Π°ΡΡ: ΠΏΠ΅ΡΠ΅ΡΠ°Π΄ΠΊΠΈ ΠΏΠΎΡΠ΅ΠΊ ΠΎΡ ΠΠ0-Π½Π΅ΡΠΎΠ²ΠΌΠ΅ΡΡΠΈΠΌΡΡ
Π΄ΠΎΠ½ΠΎΡΠΎΠ² ΠΈΠΌΠ΅ΡΡ ΠΏΡΠ°Π²ΠΎ Π½Π° ΡΡΡΠ΅ΡΡΠ²ΠΎΠ²Π°Π½ΠΈΠ΅
Noninterceptive method to measure longitudinal Twiss parameters of a beam in a hadron linear accelerator using beam position monitors
A new method of measuring of the rms longitudinal Twiss parameters of a beam in linear accelerators is presented. It is based on using sum signals from beam position monitors sensitive to the longitudinal charge distribution in the bunch. The applicability of the method is demonstrated on the superconducting section of the Oak Ridge Spallation Neutron Source linear accelerator. The results are compared to a direct measurement of the bunch longitudinal profiles using an interceptive bunch shape monitor in the linac warm section of the same accelerator. Limitations of the method are discussed. The method is fast and simple, and can be used to obtain the initial parameters for the longitudinal matching in linear accelerators where interceptive diagnostics are not desirable
Recommended from our members
A Parallel Extension of the UAL Environment
The deployment of the Unified Accelerator Library (UAL) environment on the parallel cluster is presented. The approach is based on the Message-Passing Interface (MPI) library and the Perl adapter that allows one to control and mix together the existing conventional UAL components with the new MPI-based parallel extensions. In the paper, we provide timing results and describe the application of the new environment to the SNS Ring complex beam dynamics studies, particularly, simulations of several physical effects, such as space charge, field errors, fringe fields, and others